ArticleMSMR2025
Ovarian dysfunction and polycystic ovary syndrome in the U.S. military active component, 2014-2023.
Article in MSMR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This retrospective cohort study examined ovarian dysfunction diagnosis incidence among female active component service members in the U.S. military from 2014 to 2023 using medical encounter data from the Defense Medical Surveillance System. Ovarian dysfunction diagnosis incidence gradually increased during this period, driven almost entirely by polycystic ovary syndrome (PCOS), of which the incidence increased from 32.0 cases per 10,000 person-years in 2014 to 60.3 cases per 10,000 person-years in 2023. Increases occurred among all demographic subcategories. This study also assessed independent association between ovarian dysfunction and socio-demographic and medical covariates, including COVID-19 infection and vaccination status. History of obesity had the strongest association with PCOS incidence, with an adjusted incident rate ratio (aIRR) of 2.5 and 95% confidence interval (CI) of 2.3-2.6. COVID-19 infection was modestly associated with PCOS incidence (aIRR 1.2; 95% CI, 1.1-1.3). COVID-19 vaccination status was not independently associated with increased PCOS incidence. A potential contributing factor of increased PCOS diagnosis incidence is that recent updates to the diagnostic criteria enabled more clinical and telehealth diagnoses. The increased incidence may also reflect the increasing rate of obesity and other related health burdens in the U.S. military. Incidence of diagnosis of ovarian dysfunction, driven almost entirely by PCOS, increased steadily among female active component service members from 2014 to 2023. This increase in incidence was observed in all demographic subgroups and had the strongest independent association with pre-existing obesity.
Indexed as
Identifiers
39965137PMC11844305What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.